| dc.contributor.author |
Prachayasittikul S. |
|
| dc.contributor.author |
Worachartcheewan A. |
|
| dc.contributor.author |
Nantasenamat C. |
|
| dc.contributor.author |
Chinworrungsee M. |
|
| dc.contributor.author |
Sornsongkhram N. |
|
| dc.contributor.author |
Ruchirawat S. |
|
| dc.contributor.author |
Prachayasittikul V. |
|
| dc.date.accessioned |
2021-04-05T03:35:38Z |
|
| dc.date.available |
2021-04-05T03:35:38Z |
|
| dc.date.issued |
2011 |
|
| dc.identifier.issn |
2235234 |
|
| dc.identifier.other |
2-s2.0-79151482944 |
|
| dc.identifier.uri |
https://ir.swu.ac.th/jspui/handle/123456789/14570 |
|
| dc.identifier.uri |
https://www.scopus.com/inward/record.uri?eid=2-s2.0-79151482944&doi=10.1016%2fj.ejmech.2010.12.009&partnerID=40&md5=2174a7714d042ee5e89f1cfb500ed788 |
|
| dc.description.abstract |
Considering that some thiopyrimidines were previously reported as potential therapeutics, the present study achieved novel analogs of bioactive 2-substituted thiopyrimidines-4-(3H)-ones via base catalyzed alkylation reaction of 2-thiouracil using alkyl and aralkyl bromides. The title compounds were 2-(1-butylthio)pyrimidine-4(3H)-one (5a), 2-(2-butylthio)pyrimidine-4(3H)-one (5b), 2-(cyclohexylmethylthio)pyrimidine-4(3H)-one (5c), 2-(benzylthio) pyrimidine-4(3H)-one (5d) and 2-(1-adamantylthio)pyrimidine-4(3H)-one (5e). Bioactivity tests revealed that thiopyrimidines 5a, 5c, 5d and 5e exhibited antimicrobial activity. The thiopyrimidine-4-one (5c) showed complete inhibition against Streptococcus pyogenes and Branhamella catarrhalis as well as antifungal action against Candida albicans. Significantly, the 1-adamantylthiopyrimidine (5e) was shown to be the most potent cytotoxic compound against multidrug-resistant small cell lung cancer (H69AR). Their structure-activity relationships were discussed. © 2010 Elsevier Masson SAS. All rights reserved. |
|
| dc.subject |
2 (1 adamantylthio)pyrimidin 4(3h) one |
|
| dc.subject |
2 (1 butylthio)pyrimidin 4(3h) one |
|
| dc.subject |
2 (2 butylthio)pyrimidin 4(3h) one |
|
| dc.subject |
2 (benzylthio)pyrimidin 4(3h) one |
|
| dc.subject |
2 (cyclohexylmethylthio)pyrimidin 4(3h) one |
|
| dc.subject |
2 thiopyrimidine 4 one |
|
| dc.subject |
ampicillin |
|
| dc.subject |
antiinfective agent |
|
| dc.subject |
antineoplastic agent |
|
| dc.subject |
bromine derivative |
|
| dc.subject |
etoposide |
|
| dc.subject |
pyrimidine derivative |
|
| dc.subject |
thiouracil |
|
| dc.subject |
unclassified drug |
|
| dc.subject |
Aeromonas hydrophila |
|
| dc.subject |
alkylation |
|
| dc.subject |
antibacterial activity |
|
| dc.subject |
antifungal activity |
|
| dc.subject |
antimalarial activity |
|
| dc.subject |
antimicrobial activity |
|
| dc.subject |
antineoplastic activity |
|
| dc.subject |
article |
|
| dc.subject |
Bacillus cereus |
|
| dc.subject |
Bacillus subtilis |
|
| dc.subject |
cancer resistance |
|
| dc.subject |
Candida albicans |
|
| dc.subject |
Citrobacter freundii |
|
| dc.subject |
controlled study |
|
| dc.subject |
Corynebacterium diphtheriae |
|
| dc.subject |
cytotoxicity |
|
| dc.subject |
drug activity |
|
| dc.subject |
drug synthesis |
|
| dc.subject |
Edwardsiella tarda |
|
| dc.subject |
Enterococcus faecalis |
|
| dc.subject |
Escherichia coli |
|
| dc.subject |
human |
|
| dc.subject |
human cell |
|
| dc.subject |
Klebsiella pneumoniae |
|
| dc.subject |
Listeria monocytogenes |
|
| dc.subject |
lung small cell cancer |
|
| dc.subject |
Micrococcus luteus |
|
| dc.subject |
Moraxella catarrhalis |
|
| dc.subject |
Morganella morganii |
|
| dc.subject |
Neisseria mucosa |
|
| dc.subject |
nonhuman |
|
| dc.subject |
Plasmodium falciparum |
|
| dc.subject |
Plesiomonas shigelloides |
|
| dc.subject |
Pseudomonas aeruginosa |
|
| dc.subject |
Salmonella choleraesuis |
|
| dc.subject |
Salmonella typhimurium |
|
| dc.subject |
Shigella dysenteriae |
|
| dc.subject |
Staphylococcus aureus |
|
| dc.subject |
Staphylococcus epidermidis |
|
| dc.subject |
Stenotrophomonas maltophilia |
|
| dc.subject |
Streptococcus pyogenes |
|
| dc.subject |
structure activity relation |
|
| dc.subject |
Vibrio cholerae |
|
| dc.subject |
Vibrio mimicus |
|
| dc.subject |
yeast |
|
| dc.subject |
Animals |
|
| dc.subject |
Anti-Bacterial Agents |
|
| dc.subject |
Antifungal Agents |
|
| dc.subject |
Antimalarials |
|
| dc.subject |
Antineoplastic Agents |
|
| dc.subject |
Candida albicans |
|
| dc.subject |
Cell Line, Tumor |
|
| dc.subject |
Cell Proliferation |
|
| dc.subject |
Dose-Response Relationship, Drug |
|
| dc.subject |
Drug Screening Assays, Antitumor |
|
| dc.subject |
Humans |
|
| dc.subject |
Mice |
|
| dc.subject |
Microbial Sensitivity Tests |
|
| dc.subject |
Molecular Structure |
|
| dc.subject |
Moraxella (Branhamella) catarrhalis |
|
| dc.subject |
Parasitic Sensitivity Tests |
|
| dc.subject |
Plasmodium falciparum |
|
| dc.subject |
Pyrimidinones |
|
| dc.subject |
Stereoisomerism |
|
| dc.subject |
Streptococcus pyogenes |
|
| dc.subject |
Structure-Activity Relationship |
|
| dc.title |
Synthesis and structure-activity relationship of 2-thiopyrimidine-4-one analogs as antimicrobial and anticancer agents |
|
| dc.type |
Article |
|
| dc.rights.holder |
Scopus |
|
| dc.identifier.bibliograpycitation |
European Journal of Medicinal Chemistry. Vol 46, No.2 (2011), p.738-742 |
|
| dc.identifier.doi |
10.1016/j.ejmech.2010.12.009 |
|